Literature DB >> 12488827

SUMO-1 co-localized with mutant atrophin-1 with expanded polyglutamines accelerates intranuclear aggregation and cell death.

Tomoya Terashima1, Hiromichi Kawai, Masashi Fujitani, Kengo Maeda, Hitoshi Yasuda.   

Abstract

To investigate the implication of small ubiquitin-related modifier-1 (SUMO-1) in the formation of neuronal intranuclear inclusions in polyglutamine diseases, we examined the localization of SUMO-1 in dentatorubral-pallidoluysian atrophy (DRPLA) brain tissues and PC12 cells expressing truncated atrophin-1 with expanded poly-glutamine stretches. SUMO-1 was co-localized with neuronal intranuclear inclusions in DRPLA brain and the DRPLA model cells, which showed that the aggregates formed by expanded polyglutamine stretches were highly SUMOlylated. In addition, to examine the role of SUMO-1 in nuclear aggregate formation and cell death, either SUMO-1 or DeltaSUMO-1, which is a SUMOlylation defective mutant lacking the C-terminal motif, was co-transfected with atrophin-1 with expanded polyglutamine stretches. Co-transfection of DeltaSUMO-1 decreased number of the cells with nuclear aggregates and consequent apoptosis of PC12 cells, both of which were markedly enhanced by co-transfection of SUMO-1 with atrophin-1 with expanded polyglutamine stretches. These results suggest that SUMO-1 is implicated in the pathogenesis of DRPLA and accelerates aggregate formation and cell death.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12488827     DOI: 10.1097/00001756-200212030-00038

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  19 in total

Review 1.  SUMO rules: regulatory concepts and their implication in neurologic functions.

Authors:  Mathias Droescher; Viduth K Chaugule; Andrea Pichler
Journal:  Neuromolecular Med       Date:  2013-08-30       Impact factor: 3.843

2.  Posttranslational modification of ataxin-7 at lysine 257 prevents autophagy-mediated turnover of an N-terminal caspase-7 cleavage fragment.

Authors:  Shona Mookerjee; Theodora Papanikolaou; Stephan J Guyenet; Vanitha Sampath; Amy Lin; Cathy Vitelli; Francesco DeGiacomo; Bryce L Sopher; Sylvia F Chen; Albert R La Spada; Lisa M Ellerby
Journal:  J Neurosci       Date:  2009-12-02       Impact factor: 6.167

Review 3.  Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease.

Authors:  Dagmar E Ehrnhoefer; Liza Sutton; Michael R Hayden
Journal:  Neuroscientist       Date:  2011-02-10       Impact factor: 7.519

4.  Neuronal intranuclear inclusion disease without polyglutamine inclusions in a child.

Authors:  Kathryn McFadden; Ronald L Hamilton; Sam J Insalaco; Lawrence Lavine; Majeed Al-Mateen; Guoji Wang; Clayton A Wiley
Journal:  J Neuropathol Exp Neurol       Date:  2005-06       Impact factor: 3.685

5.  Small ubiquitin-like modifier (SUMO) modification of the androgen receptor attenuates polyglutamine-mediated aggregation.

Authors:  Sarmistha Mukherjee; Monzy Thomas; Nahid Dadgar; Andrew P Lieberman; Jorge A Iñiguez-Lluhí
Journal:  J Biol Chem       Date:  2009-06-04       Impact factor: 5.157

Review 6.  Sumoylation in neurodegenerative diseases.

Authors:  Petranka Krumova; Jochen H Weishaupt
Journal:  Cell Mol Life Sci       Date:  2012-09-25       Impact factor: 9.261

Review 7.  SUMO and Parkinson's disease.

Authors:  Katrin Eckermann
Journal:  Neuromolecular Med       Date:  2013-08-25       Impact factor: 3.843

8.  Modulation of Abeta generation by small ubiquitin-like modifiers does not require conjugation to target proteins.

Authors:  Véronique Dorval; Matthew J Mazzella; Paul M Mathews; Ronald T Hay; Paul E Fraser
Journal:  Biochem J       Date:  2007-06-01       Impact factor: 3.857

Review 9.  Protein SUMOylation in neuropathological conditions.

Authors:  Dina B Anderson; Kevin A Wilkinson; Jeremy M Henley
Journal:  Drug News Perspect       Date:  2009-06

Review 10.  Emerging extranuclear roles of protein SUMOylation in neuronal function and dysfunction.

Authors:  Stéphane Martin; Kevin A Wilkinson; Atsushi Nishimune; Jeremy M Henley
Journal:  Nat Rev Neurosci       Date:  2007-12       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.